PCN208 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION: AN ANALYSIS FROM A SWISS HEALTHCARE SYSTEM PERSPECTIVE.

The aim of this analysis was to assess the cost-effectiveness of nivolumab as an adjuvant treatment for adult patients with melanoma with involvement of lymph nodes or metastatic disease, from a healthcare system perspective in Switzerland. Recurrence-free survival (RFS) for nivolumab and observation was estimated through an indirect treatment comparison based on patient-level data from CheckMate 238 and CA184-029 trials, since both include ipilimumab as comparator. [Extracted from the article]